JPH1160480A - Peptic ulcer treatment - Google Patents

Abstract

(57) [Problem] To provide a therapeutic agent for peptic ulcer which is safer and highly useful. SOLUTION: The therapeutic agent for peptic ulcer containing vitamin E and squalane. Furthermore, the content of vitamin E is more than 0.1% by weight and less than 99% by weight, and the content of squalane is 0.1% by weight.
The above-mentioned therapeutic agent for peptic ulcer, which is more than 1% by weight and less than 99% by weight. Formulation example: a liquid formulation comprising vitamin E, squalane and an aqueous solution of gum arabic.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

The present invention relates to a therapeutic agent for peptic ulcer.

[0002]

2. Description of the Related Art Peptic ulcer is a general term for gastric ulcer, duodenal ulcer, anastomotic ulcer and the like, and is defined as a partial mucosal defect extending below the submucosa such as the stomach or duodenum. As a pathogenesis mechanism of peptic ulcer, the balance theory is generally accepted. In other words, inside the digestive tract, the balance between aggressive factors such as acid and pepsin and protective factors such as mucous membrane, bicarbonate, and mucosal blood flow is maintained. It is believed that ulcers form when the action of protective factors is exceeded (Suzuki et al., Inspection and Technology, Vol. 23, No. 7, 466-47).
2, p. 1995). This disease is generally accompanied by persistent pain, causing a great deal of pain to the patient, and once onset, it often becomes recurrent and chronic after healing.

[0003] Drugs for treating peptic ulcer include antacids (such as sodium bicarbonate, calcium carbonate, aluminum hydroxide and magnesium hydroxide), H2 receptor antagonists (such as cimetidine, ranitidine and famotidine), and proton pump inhibitors (such as omeprazole). And sucralfate. These drugs attenuate certain aggressive factors or enhance certain protective factors in the above-mentioned balance theory, and as a result, the natural healing power of the living body is exerted to exert its effect.

[0004]

However, since there are intractable cases where the above drugs are ineffective and each drug has its own side effects, development of new drugs is desired. An object of the present invention is to provide a safer and more useful therapeutic agent for peptic ulcer in view of the above points.

[0005]

The remedy for peptic ulcer according to claim 1 is characterized by containing vitamin E and squalane.

[0006] The therapeutic agent for peptic ulcer according to claim 2 has a vitamin E content of more than 0.1% by weight and less than 99% by weight;
2. The therapeutic agent for peptic ulcer according to claim 1, wherein the content of squalane is more than 0.1% by weight and less than 99% by weight.

[0007] The above-mentioned vitamin E refers to tocopherol (vitamin E) and its derivatives. Examples of those listed in the Japanese Pharmacopoeia include tocopherol acetate (vitamin E acetate) and tocopherol succinate (vitamin E succinate). Acid ester). Other than the above, for example, α-tocopherol, β
-Tocopherol, γ-tocopherol, δ-tocopherol, tocopherol nicotinate (vitamin E nicotinate), tocopherol phosphate (vitamin E phosphate), natural vitamin E, and the like.
However, the present invention is not limited thereto.
Is also included. It is generally known that vitamin E has no side effects even if it is excessively taken, has little local irritation, and is safe.

[0008] The above-mentioned squalane is fish in the deep sea, especially in shark liver oil or vegetable oil such as olive oil.
It is a saturated hydrocarbon obtained by reducing squalene which is an unsaturated hydrocarbon present in rice bran oil, wheat germ oil, sesame oil, cottonseed oil and the like. Further, a synthetic squalane obtained by using geranylacetone and an acetylene compound as raw materials is also included. In addition, as described above, squalane is contained in a large amount in foods, has a track record as an additive for cosmetics, and is generally known to be locally safe.

Vitamin E in the therapeutic agent for peptic ulcer of the present invention
When the content of ulcer decreases, the effect of promoting ulcer healing becomes insufficient, and even when it increases, the effect of promoting ulcer healing does not increase significantly depending on the content. Preferably, it is more preferably from 10 to 95% by weight, particularly preferably from 20 to 50% by weight.

When the content of squalane in the therapeutic agent for peptic ulcer of the present invention decreases, the effect of promoting ulcer healing becomes insufficient, and even if it increases, the effect of promoting ulcer healing does not increase significantly depending on the content. Therefore, it is preferably more than 0.1% by weight and less than 99% by weight, more preferably 5 to 90% by weight, and particularly preferably 10 to 50% by weight.

Vitamin E in the therapeutic agent for peptic ulcer of the present invention
And the squalane content is preferably a combination of a vitamin E content of more than 0.1% by weight and less than 99% by weight, and a squalane content of more than 0.1% by weight and less than 99% by weight. Content of 10 to 95% by weight,
The content of squalane is more preferably 5 to 90% by weight,
Particularly preferably, the content of vitamin E is 20 to 50% by weight, and the content of squalane is 10 to 50% by weight.

[0012] The therapeutic agent for peptic ulcer of claims 1 and 2 of the present invention may contain various pharmaceutical carriers. As the carrier, a filler, disintegrant, bulking agent, binder, coloring agent, flavoring agent, pH adjusting agent, solubilizing agent, suspending agent, which is usually used for preparing a drug according to the dosage form, Agents (eg, gum arabic solution), buffers, stabilizers, preservatives, qualifiers,
Examples include surfactants, lubricants, excipients, and the like. Also,
It can be used as a liquid as it is or by selecting an appropriate solvent.

[0013] The dosage form of the therapeutic agent for peptic ulcer of the present invention includes tablets, pills, powders, suspensions, emulsions, granules, syrups, troches, capsules, etc., in addition to the above-mentioned liquid preparations. Is mentioned.

The dose of the therapeutic agent for peptic ulcer of the present invention is appropriately selected depending on the purpose of use, symptoms, etc., but is preferably 500 mg to 20 g per day, and is administered in 1 to 4 doses / day. No problem.

[0015]

DESCRIPTION OF THE PREFERRED EMBODIMENTS Examples of the present invention and comparative examples will be described. Example 1 and Comparative Example 1 A predetermined amount (% by weight) of tocopherol acetate (manufactured by BASF), squalane (manufactured by Maruha), and a 5% by weight aqueous solution of gum arabic shown in Table 1 were uniformly mixed to prepare a liquid agent. Obtained.

Test Example The method of Takagi et al. (Jpn. J. Pharmacol. 1)
9, 418-426, 1969) to create a rat acetate ulcer model. That is, a weight of 200 to 25
A 0 g SD male rat was laparotomized under ether anesthesia, and 20 μl of a 20% by weight acetic acid aqueous solution was injected under the gastric serosa.
The abdomen was sutured and an acetate ulcer was induced. 48 hours after ulcer induction, 5 ml / kg of the solution of Example 1 was orally administered. Thereafter, administration of the drug was performed twice a day for 14 consecutive days. To the rats of the control group, the liquid preparation of Comparative Example 1 was similarly administered. This test used 20 rats in each group.

Twenty-four hours after the last administration, the rats are necropsied, the stomach is excised and the presence or absence of ulcers is examined to calculate the percentage of individuals without ulcers (healing rate). The area was measured. Table 1 shows the results.

[0018]

[Table 1]

In the group to which the therapeutic agent for peptic ulcer of the present invention was administered, the number of ulcers healed was clearly higher and the area of the ulcer was clearly smaller than the control group. That is, the therapeutic agent for peptic ulcer of the present invention has a peptic ulcer healing promoting effect.

[0020]

The composition of the therapeutic agent for peptic ulcer according to claim 1 is as described above, and the effect of vitamin E and squalane exerts a peptic ulcer healing promoting effect.

[0021] The composition of the therapeutic agent for peptic ulcer according to claim 2 is as described above, and contains vitamin E and squalane in a specific range, so that the peptic ulcer healing promoting effect is further enhanced.

Accordingly, the present invention provides a safer and more useful agent for treating peptic ulcer.

Claims (2)

[Claims] 1. A therapeutic agent for peptic ulcer, comprising vitamin E and squalane. 2. A vitamin E content of more than 0.1% by weight and less than 99% by weight, and a squalane content of 0.1% by weight.
2. The amount is more than 99% by weight.
The therapeutic agent for peptic ulcer according to the above.